Akebia Therapeutics (NASDAQ:AKBA) Raised to “Hold” at StockNews.com
StockNews.com upgraded shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from a sell rating to a hold rating in a report issued on Monday morning. Separately, HC Wainwright reiterated a “buy” rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research note on Thursday, January 23rd. Read Our Latest Analysis […]
StockNews.com upgraded shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from a sell rating to a hold rating in a report issued on Monday morning. Separately, HC Wainwright reiterated a “buy” rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research note on Thursday, January 23rd. Read Our Latest Analysis […]
